IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
Background High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective.Methods I...
Main Authors: | Sjoerd H van der Burg, Ramon Arens, Thorbald van Hall, Elham Beyranvand Nejad, Jan Willem Kleinovink, Camilla Labrie, Marit J van Elsas, Hans-Willi Mittrücker, Kees L M C Franken, Sylvia Heink, Thomas Korn |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/9/4/e002460.full |
Similar Items
-
Future Challenges in Cancer Resistance to Immunotherapy
by: Marit J. van Elsas, et al.
Published: (2020-04-01) -
PD-L1 immune suppression in cancer: Tumor cells or host cells?
by: Jan Willem Kleinovink, et al.
Published: (2017-07-01) -
TEIPP peptides: exploration of unTAPped cancer antigens
by: Koen A. Marijt, et al.
Published: (2019-08-01) -
The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy
by: Els M. E. Verdegaal, et al.
Published: (2017-09-01) -
The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.
by: Eleni Panagioti, et al.
Published: (2016-09-01)